BHCM
NAGE

Brevan Howard Capital Management’s Niagen Bioscience NAGE Stock Holding History

Brevan Howard Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,291
Closed -$96K – 2362
2025
Q3 		$96K Buy
+10,291
New +$104K ﹤0.01% 1869
2024
Q2 		– Sell
-48,026
Closed -$167K – 1456
2024
Q1 		$167K Buy
+48,026
New +$88.9K ﹤0.01% 835

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Brevan Howard Capital Management's NAGE Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Niagen Bioscience (NAGE) in Q4 2025, closing a stake of 10,291 shares — an estimated $96K sold.

Brevan Howard Capital Management first reported a position in NAGE in Q1 2024 and held it in 2 quarters. The position peaked at $167K in Q1 2024. 169 funds tracked by Wall St. Rank hold NAGE as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining Niagen Bioscience position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 10,291 Niagen Bioscience shares in Q4 2025, an estimated $96K.
  • Brevan Howard Capital Management first reported a position in Niagen Bioscience in Q1 2024 and held it in 2 quarters.
  • Brevan Howard Capital Management's Niagen Bioscience position peaked at $167K in Q1 2024.
  • 169 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.